Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?

Dermatology. 2007;214(4):275-7. doi: 10.1159/000100876.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use*
  • Pemphigus / drug therapy*
  • Pemphigus / immunology
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab